4/22/2011

XTL Biopharmaceutical is seeking FDA orphan-drug designation for an erythropoietin drug to treat patients with multiple myeloma, a type of blood cancer. The treatment is in midstage development.

Full Story:
Globes (Israel)

Related Summaries